Cargando…

Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma

SIMPLE SUMMARY: Multiple Myeloma (MM) remains incurable due to high relapse rates and fast development of drug resistances. Monoclonal antibodies (mAb) have revolutionized MM treatment, opening the door to chemotherapy-free yet curative treatments. Nevertheless, antibody-based therapies face several...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amundarain, Ane, Pastor, Fernando, Prósper, Felipe, Agirre, Xabier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657029/ https://www.ncbi.nlm.nih.gov/pubmed/36358889 http://dx.doi.org/10.3390/cancers14215471

Ejemplares similares

The Role of lncRNAs in the Pathobiology and Clinical Behavior of Multiple Myeloma
por: Carrasco-León, Arantxa, et al.
Publicado: (2021)

Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma
por: Valcárcel, Luis V., et al.
Publicado: (2021)

Aptamer-iRNAs as Therapeutics for Cancer Treatment
por: Soldevilla, Mario M., et al.
Publicado: (2018)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Aptamers: A New Technological Platform in Cancer Immunotherapy
por: Pastor, Fernando
Publicado: (2016)

Long Non-Coding RNAs in Haematological Malignancies
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2013)

DNA Methylation of Enhancer Elements in Myeloid Neoplasms: Think Outside the Promoters?
por: Ordoñez, Raquel, et al.
Publicado: (2019)

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
por: Botta, Cirino, et al.
Publicado: (2021)

Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma
por: Carrasco-Leon, Arantxa, et al.
Publicado: (2021)

HDAC Inhibitors in Acute Myeloid Leukemia
por: San José-Enériz, Edurne, et al.
Publicado: (2019)

Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions
por: Raus, Svjetlana, et al.
Publicado: (2011)

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
por: Kumar, Shaji, et al.
Publicado: (2022)

Is immunotherapy here to stay in multiple myeloma?
por: Rodríguez-Otero, Paula, et al.
Publicado: (2017)

The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation
por: Chatonnet, Fabrice, et al.
Publicado: (2020)

The Landscape of lncRNAs in Multiple Myeloma: Implications in the “Hallmarks of Cancer”, Clinical Perspectives and Therapeutic Opportunities
por: Saltarella, Ilaria, et al.
Publicado: (2022)

Correction: Ordoñez, et al.; DNA Methylation of Enhancer Elements in Myeloid Neoplasms: Think Outside the Promoters? Cancers 2019, 11, 1424
por: Ordoñez, Raquel, et al.
Publicado: (2020)

CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
por: Rodríguez-Otero, Paula, et al.
Publicado: (2020)

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2022)

Recent Progress and Opportunities for Nucleic Acid Aptamers
por: Byun, Jonghoe
Publicado: (2021)

Quantitative Imaging and Radiomics in Multiple Myeloma: A Potential Opportunity?
por: Tagliafico, Alberto Stefano, et al.
Publicado: (2021)

New Frontiers in the Treatment of Multiple Myeloma
por: Hwang, Janice Jin, et al.
Publicado: (2006)

Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities
por: Pastor-Fernández, Gloria, et al.
Publicado: (2020)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

Challenges and Opportunities for Small Molecule Aptamer Development
por: McKeague, Maureen, et al.
Publicado: (2012)

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
por: Leblay, Noémie, et al.
Publicado: (2020)

Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
por: Nakamura, Yoshikazu
Publicado: (2021)

A Review of Therapeutic Aptamer Conjugates with Emphasis on New Approaches
por: Bruno, John G.
Publicado: (2013)

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
por: Swan, Dawn, et al.
Publicado: (2023)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Escort Aptamers: New Tools for the Targeted Delivery of Therapeutics into Cells
por: Davydova, A.S., et al.
Publicado: (2011)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Aptamers in the Therapeutics and Diagnostics Pipelines
por: Kaur, Harleen, et al.
Publicado: (2018)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum
por: Tapia-Alveal, Claudia, et al.
Publicado: (2020)

New therapies in multiple myeloma
por: Merchionne, F., et al.
Publicado: (2007)

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
por: Garcia-Gomez, Antonio, et al.
Publicado: (2021)

Explainable artificial intelligence for precision medicine in acute myeloid leukemia
por: Gimeno, Marian, et al.
Publicado: (2022)

Therapeutics to harness the immune microenvironment in multiple myeloma
por: Ignatz-Hoover, James J., et al.
Publicado: (2022)

Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
por: Weiser Drozdkova, Denisa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gal4cfgbn0k13f8iq8tr20257l